Advanced Search

Decree No. 2014-1556 Of December 22, 2014, On The Publication Of The Amendment To Annex I To The International Convention Against Doping In Sport, Adopted In Paris On 17 November 2014

Original Language Title: Décret n° 2014-1556 du 22 décembre 2014 portant publication de l'amendement à l'annexe I de la convention internationale contre le dopage dans le sport, adopté à Paris le 17 novembre 2014

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
Learn more about this text...

Information on this text

Keywords

SPORTS , INTERNATIONAL AGREEMENT , MULTILATERAL AGREEMENT , INTERNATIONAL AGREEMENT , SPORTF , SCOPE , STIMULING , SUBSTANCE DOPANTING , INTERDICTION , COMPETITION SPORTIVE , ANTIDING , LUTTE CONTROL


JORF no.0297 of 24 December 2014 page 21823
text No. 12



Decree No. 2014-1556 of 22 December 2014 on the publication of the amendment to Schedule I of the International Convention against Doping in Sport, adopted in Paris on 17 November 2014 (1)

NOR: MAEJ1428808D ELI: https://www.legifrance.gouv.fr/eli/decret/2014/12/22/MAEJ1428808D/jo/texte
Alias: https://www.legifrance.gouv.fr/eli/decret/2014/12/22/2014-1556/jo/texte


President of the Republic,
On the report of the Prime Minister and the Minister for Foreign Affairs and International Development,
Considering the Constitution, in particular articles 52 to 55;
Having regard to the amended Decree No. 53-192 of 14 March 1953 concerning the ratification and publication of the international commitments undertaken by France;
In view of Decree No. 2007-503 of 2 April 2007 on the publication of the International Convention against Doping in Sport (a set of two annexes), adopted in Paris on 19 October 2005;
Having regard to Decree No. 2008-35 of 10 January 2008 on the publication of the amendment to the annex to the Convention against Doping, adopted by the follow-up group at its 26th meeting on 12 November 2007 in Madrid;
In view of Decree No. 2009-93 of 26 January 2009 on the publication of the amendment to the Annex to the Convention against Doping, adopted on 13 November 2008 in Strasbourg, and Annex 1 of the International Convention against Doping in Sport, adopted in Paris on 17 November 2008;
Having regard to Decree No. 2010-134 of 10 February 2010 on the publication of the amendment to the Annex to the Convention against Doping, adopted on 18 November 2009 in Strasbourg, and to Annex 1 of the International Convention against Doping in Sport, adopted in Paris on 28 October 2009;
Having regard to Decree No. 2010-1578 of 16 December 2010 on the publication of the amendment to the Annex to the Convention against Doping, adopted on 8 and 9 November 2010 in Strasbourg, and to Annex 1 of the International Convention against Doping in Sport, adopted in Paris on 17 November 2010;
Having regard to Decree No. 2011-1947 of 23 December 2011 on the publication of the amendment to the Annex to the Convention against Doping, adopted on 7 November 2011 in Strasbourg, and to Annex 1 of the International Convention against Doping in Sport, adopted in Paris on 14 November 2011;
Having regard to Decree No. 2012-1426 of 19 December 2012 on the publication of the amendment to the annex to the Convention against Doping, adopted in Paris on 13 November 2012, and to Annex 1 of the International Convention against Doping in Sport, adopted in Paris on 12 November 2012;
In view of Decree No. 2013-1286 of 27 December 2013 on the publication of the amendment to the annex to the convention against doping, adopted in Strasbourg on 14 November 2013, and Annex 1 of the international convention against doping in sport, adopted in Paris on 11 November 2013,
Decrete:

Article 1


The amendment to Appendix I of the International Convention against Doping in Sport, adopted in Paris on 17 November 2014, will be published in the Official Journal of the French Republic.

Article 2


The Prime Minister and the Minister for Foreign Affairs and International Development are responsible, each with respect to him, for the execution of this decree, which will be published in the Official Journal of the French Republic.

  • Annex


    Annex


    AMENDMENT TO THE ANNEX I OF THE INTERNATIONAL CONVENTION AGAINST DOPAGE IN THE SPORT, ADOPTED BY THE 17 NOVEMBER 2014
    LIST OF INTERDICTIONS - STANDARD INTERNATIONAL
    LIST OF PROHIBITIONS 2015
    CODE MONDIAL ANTIDOPAGE
    Effective January 1, 2015


    In accordance with Article 4.2.2 of the World Anti-Doping Code, all prohibited substances must be considered as "specified substances" except substances in classes S1, S2, S4.4, S4.5, S6.a, and prohibited methods M1, M2 and M3.


    SUBSTANCES AND METHODS IN PERMANENCE (EN ET HORS COMPÉTITION)
    SUBSTANCES INTERDITES


    S0. SUBSTANCES NON APPROVED
    Any pharmacological substance not included in a section of the List below and that is not currently approved for therapeutic use in humans by a regulatory government authority of Health (e.g. preclinical or clinical development drugs or that are no longer available, medicines in a manner, substances approved only for veterinary use) is permanently prohibited.
    S1. ANABOLISANT AGENTS
    Anabolic agents are forbidden.
    1. Androgenic anabolic steroids (SAA)
    a. Exogenous SAA*, including:
    1-androstènediol (5α-androst-1-ène-3β,17β-diol); 1-androstènedione (5α-androst-1-ène-3,17-dione) ; bolandiol (estr-4-ène-3β,17β-diol); bolasterone; boldenone; boldione (androsta-1,4-diène-3,17-dione); calusterone; enclosurebol; danazol ([1,2] oxazolo [4',5': 2,3] pregna-4-ène-20-yn-17α-ol); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-diène-3-one); deoxymethyltestosterone (17α-methyl-5α-androst-2-ène-17β-ol); drostanolone; ethylestrenol (19-norprégna-4-ène-17α-ol) ; fluoxymesterone ; formationbolone ; ferazabol (17α-methyl [1,2.5] oxadiazolo [3',4': 2,3] -5α-androstane-17β-ol); gestrinone; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-ène-3-one) ; mestanolone ; mesterolone ; metandinone (17β-hydroxy-17α-methylandrosta-1,4-diène-3-one); meternolone; methandriol; methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstane-3-one); methyldenolon (17β-hydroxy-17α-methylestra-4,9-diène-3-one); methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-ène-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltestosterone; metribolone (methyltrienolone, 17β-hydroxy-17α-methylestra-4,9,11-triene-3-one); mibolone; nandrolone; 19-norandrostendione (estr-4-ene-3,17-dione); norboletone; norclostebol; Norethandrolone ; oxabolone ; oxandrolone ; oximesterrone; oxymetholone; prostanozol (17β-[(tétrahydropyrane-2-yl) oxy]-1'H-pyrazolo[3,4: 2,3]-5α-androstane); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α-androst-1-ène-3-one) ; tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-prégna-4,9,11-triène-3-one); trenbolone (17β-hydroxyestr-4,9,11-triène-3-one);
    and other substances having a similar chemical structure or a similar biological effect(s).
    b. Endogenous SAA** by exogenous administration:
    Androstènediol (androst-5-ène-3β,17β-diol); androstènedione (androst-4-ène-3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one) ; prasterone (dehydroepandrosterone, DHEA, 3β-hydroxyandrost-5-ene-17-one) ; testosterone ; and the following metabolites and isomers, including but not limited to:
    5α-androstane-3α,17α-diol; 5α-androstane-3α, 17β-diol; 5α-androstane-3β, 17α-diol; 5α-androstane-3β,17β-diol; 5β-androstane-3α,17β-diol; androst-4-ene-3α, 17α-diol; androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol); androst-5-ene-3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α-diol; 4-androstènediol (androst-4-ène-3β,17β-diol); 5-androstènedione (androst-5-ène-3,17-dione); epidihydrotestosterone; epitestosterone; etiocholanolone; 3α-hydroxy-5α-androstan-17-one; androsterone (3β-hydroxy-5α-androstan-17-one) ; 7α-hydroxy-DHEA; 7β-hydroxy-DHEA; 7-keto-DHEA; 19-norandrosterone; 19-norétiocholanolone.
    2. Other anabolic agents
    Includes without limitation:
    Clenbuterol, selective modulators of androgenic receptors (SARMs, e.g. andarine and ostarine), tibolone, zéranol and zilpatrol.
    For the purposes of this document:
    * "exogenous" means a substance that cannot usually be produced naturally by the human body.
    * "endogenous" means a substance that can usually be produced naturally by the human body.
    S2. PEPTIDICAL HORMONS, CROISSANCE FACTERS, APPARENT AND MEMETICAL SUBSTANCES


    The following substances and other substances with a similar chemical structure or a similar biological effect(s) are prohibited:
    1. Erythropoietin receptor agonists:


    1.1 Stimulating agents of erythropoiesis (ESAs) by e.g. darbepoetin (DEPO); erythropoietia (EPO); EPO-Fc; methoxy polyethylene glycol-epoetin beta (CERA); EPO (EMP) mimetic peptides, e.g. CNTO 530 and petginesatide;
    1.2 Non-Erythropoietic Agonists of the EPO Receptor, e.g. ARA-290 asialo-EPO and EPO carbamylée;


    2. Hypoxie inductible factor stabilizers (HIF) e.g. cobalt and FG-4592; and HIF activators e.g. xenon, argon;
    3. chorionic Gonadotrophin (CG) and luteinizing hormone (LH) and their release factors, e.g. busereline, gonadoreline and triptoreline, prohibited in male sports only;
    4. Corticotrophins and their factors of liberation, e.g. corticoreline;
    5. Growth Hormone (GH) and its release factors including growth hormone release hormone (GHRH) and its analogues, for example. CJC-1295, sermoreline and tésamoreline; growth hormone secretagons (GHS), e.g. ghreline and ghreline mimetics, e.g. anamorreline and ipamoreline; and growth hormone liberators peptides (GHRPs), e.g. alexamoreline, GHRP-6, hexareline.


    Additional growth factors prohibited:
    Platelet-derived growth factor (GDP); vascular endothelial growth factor (VEGF); growth factor similar to insulin-1 (IGF-1) and its analogues; hepatocyte growth factor (HGF); fibroblastic growth factors (FGF); mechanical growth factors (MGF); as well as any other growth factor influencing in muscle, tendon or ligament, protein synthesis/degradation, vascularization, energy use, regenerative capacity or change of fibre type.
    S3. BÊTA-2 AGONISTS
    All agonist beta-2, including all optical isomers, e.g. d- and if applicable, are prohibited.


    Except:
    - inhaled salbutamol (maximum 1,600 micrograms per 24 hours),
    - inhaled formoterol (maximum dose from 54 micrograms per 24 hours); and
    - inhaled salmeterol in accordance with the therapeutic administration schemes recommended by manufacturers.


    The presence in the urine of salbutamol at a concentration greater than 1000 ng/mL or formoterol at a concentration greater than 40 ng/mL will be presumed not to be an intentional therapeutic use and will be considered as a result of abnormal analysis (RAA), unless the athlete proves by a controlled pharmacokinetic study that this abnormal result is indeed the consequence of the use of a maximum dose by
    S4. HORMONAL AND METHODS
    The following hormonal hormones and modulators are prohibited:
    1. Aromatase inhibitors, including but not limited to: aminoglutethhimide, anastrozole, androsta-1,4,6-trine-3,17-dione (androstatrenedione), 4-androstène-3,6,17 trione (6-oxo), exemestane, formstane, letrozole and testolactone.
    2. Selective moderators of estrogen receptors (SERM), including without limitation: raloxifene, tamoxifene and toremifene.
    3. Other anti-estrogogenic substances, including but not limited to: clomifene, cyclofenil and fulvestrant.
    4. Modifying agents of myostatin function(s), including without limitation: myostatin inhibitors.
    5. Metabolic modulators:
    5.1 Activators of the kinase protein activated by the AMP, e.g. AICAR and agonist receptor activated by proliferators of δ (PPARδ), e.g. GW 1516;
    5.2.
    5.3 Trimetazidine.
    S5. DIURETIQUES ET AGENTS MASQUANTS
    The following diuretics and masking agents are prohibited, as well as other substances with a similar chemical structure or a similar biological effect(s).
    Includes without limitation:


    - Desmopressine ; probenecide ; plasma substitutes, e.g. glycerol and intravenous administration of albumin, dextran, hydroxyethylamidon and mannitol.
    - Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan.


    Except:


    - the drospirin; pamabroma; and the topical administration of dorzolamide and brinzolamide;
    - the local administration of felypressin in dental anesthetic.


    The detection of any quantity of the following substances in the sport sample permanently or in competition, if applicable, is subject to a threshold level: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, together with a diuretic or a masking agent, will be considered as a result of abnormal analysis unless the athlete has an AUT approved for this substance.


    METHODS


    M1. MANIPULATION OF SANGUAGE OR SANGUAGE
    The following is prohibited:
    1. Administration or reintroduction of any amount of autologous, allogenic (homologist) or heterogeneous blood or red blood cells of any origin in the circulatory system.
    2. Artificial improvement in the consumption, transport or release of oxygen.
    Includes, but not limited to:
    Perfluorinated chemicals; Efaproxiral (RSR13) and modified hemoglobin products, e.g., hemoglobin-based blood substitutes and reticulated hemoglobin-based products, but excluding oxygen supplementation.
    3. Any intravascular manipulation of blood or blood component(s) by physical or chemical methods.
    M2. CHEMICAL AND PHYSICAL MANIPULATION
    The following is prohibited:
    1. Falsification, or attempted falsification, in order to alter the integrity and validity of samples collected during doping control.
    Includes, but not limited to:
    The substitution and/or alteration of urine, e.g. proteases.
    2. Intravenous infusions and/or injections of more than 50 mL per 6-hour period, except those legitimately received in hospital admissions, surgical procedures or clinical examinations.
    M3. GENERAL DOPAGE
    The following, having the potential capacity to improve sports performance, is prohibited:
    1. Transfer of nucleic acid polymers or nucleic acid analogs;
    2. Use of normal or genetically modified cells.


    SUBSTANCES AND METHODS IN COMPETITION


    In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited in competition:


    SUBSTANCES INTERDITES


    S6. STIMULANTS
    All stimulants, including all optical isomers, e.g. d- and if applicable, are prohibited.
    Stimulants include:
    a Stimulants not specified:
    Adrafinil ; afeepramone ; amphetamine ; amfétaminil ; amiphénazol ; benfluorex ; benzylpipérazine ; bromantan ; clobenzorex ; cocaine ; cropropamide ; crotétamide ; fencamine; penetylline; fenfluramine; fenproporex; fonturacétam [4-phenylpiracétam (carphedon)]; furfénorex; mefénorex; mephentermine; mesocarb; metametamine (d-); p- methylamphetamine; modafinil; norfenfluramine; phendimétrazine; phentermine ; prenylamine ; and prolintane.
    A stimulant that is not specifically named in this section is a specified substance.
    b Specified stimulants (examples):
    Benzfetamine; cathine**; cathinone and its analogues, e.g. mephedrone, methedrone and α- pyrrolidinovalerophenol; dimethylamphetamine; ephedrine***; epinephrine**** (adrenaline); etamivan; etilamfenamine; etilefrine; famprofazone; fenbutrazate; fencamfamine; heptaminol; hydroxyamphetamine (parahydroxyamphetamine); isomethepten; levmetamfetamine; meclofenexate; methylenedio-xymethamphetamine; methylephedrine***; methylhexaneamine (dimethylpentylamine); methylphenidate; nicethamide; norfenefrine; octopamine; oxilofrine (methylsynephrine); pemonline; pentetrazol; phenmethylamine and its derivatives; phenmetrazine; phenpromethamine; propylhexédrine; pseudoephedrine***** selegiline; sibutramine; strychnine; tenamfetamine (methylenedioxyamphetamine); tuaminoheptane; and other substances having a similar chemical structure or similar biological effect(s).
    Except:
    Imidazole derivatives in topical/ophthalmic application and stimulants in the 2015 Monitoring Program*.
    * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol and synephrine: these substances in the 2015 Monitoring Program and are not considered prohibited substances.
    ** Cathine: forbidden when its concentration in the urine exceeds 5 micrograms per millilitre.
    *** Ephedrine and methylephedrine: prohibited when their respective concentrations in urine exceed 10 micrograms per millilitre.
    **** Epinephrine (adrenaline): is not prohibited for local use, e.g. by nasal or ophthalmological or co-administered with local anesthetics.
    ***** Pseudoéphedrine: forbidden when its concentration in the urine exceeds 150 micrograms per millilitre.
    S7. NARCOTIQUES
    Forbidden:
    Buprenorphine; dextromoramide; diamorphine (heroin); fentanyl and its derivatives; hydromorphone; methadone ; morphine ; oxycodone ; oxymorphone ; pentazocin and pethidine.
    S8. CANNABINOCIDES
    Forbidden:


    - Δ9-tetrahydrocannabinol (THC) natural, e.g. cannabis, haschisch, and marijuana, or synthetic.
    - cannabimimetic, for example. "Spice", JWH-018, JWH-073, HU-210 are prohibited.


    S9. GLUCOCORTICOÏDES
    All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal.


    SUBSTANCES IN SPORTS


    P1. ALCOOL
    Alcohol (ethanol) is prohibited in competition only in the following sports. The detection will be performed by ethylometry and/or blood analysis. The violation threshold is equivalent to a blood alcohol concentration of 0.10 g/L.


    - Aeronautics (FAI);
    - Automobile (FIA);
    - Motorcycling (FIM) ;
    - Motonautics (UIM);
    - Archery (WA).


    P2. BÊTA-BLOQUANTS
    Beta-blockers are prohibited in competition only, in the following sports and also banned out of competition if indicated.
    Automobile (FIA).
    Leg (all disciplines) (WCBS).
    Darts (WDF).
    Golf (IGF).
    Ski (FIS) for ski jump, freestyle jump /halfpipe and snowboard halfpipe/big air.
    Subaquatic sports (CMAS) for dynamic apnea with or without palms, free immersion apnea, constant weight apnea with or without palms, variable weight apnea, Jump Blue apnea, static apnea, underwater hunting and target shooting.
    Fire (ISSF, IPC)*.
    Archery (WA)*.
    * Also forbidden out of competition.
    Include without limitation:
    Acebutolol; alprenolol; aténolol; betaxolol ; bisoprolol ; bunolol ; cartéolol ; carvédilol ; céliprolol ;esmolol ; labétalol; lévobunolol ; metipranolol ; metoprolol; nadolol ; oxprenolol ; pindolol ; propranolol ; sotalol et timolol.


Done on 22 December 2014.


François Hollande

By the President of the Republic:


The Prime Minister,

Manuel Valls


Minister for Foreign Affairs and International Development,

Laurent Fabius

(1) This amendment comes into force on 1 January 2015.
Download the document in RTF (weight < 1MB) Extrait du Journal officiel électronique authentifié (format: pdf, weight : 0.27 Mo) Download the document in RDF (format: rdf, weight < 1 MB)